{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T11:45:21Z","timestamp":1767008721335},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.antiviral.2015.10.009","type":"journal-article","created":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T14:04:52Z","timestamp":1445781892000},"page":"193-203","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the \u201cmagic bullet\u201d to kill cccDNA"],"prefix":"10.1016","volume":"123","author":[{"given":"Ejuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kosinska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengji","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Roggendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2015.10.009_b0005","first-page":"5","article-title":"HDV2 O-09: REP 2139 monotherapy and combination therapy with pegylated interferon: safety and potent reduction of HBsAg and HDV RNA in Caucasian patients with chronic HBV\/HDV co-infection","author":"Bazinet","year":"2015","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2015.10.009_b0010","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2014.07.005","article-title":"Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation","volume":"6","author":"Bengsch","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0015","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1008354","article-title":"T cell receptor-therapy in HBV-related hepatocellularcarcinoma","volume":"4","author":"Bertoletti","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.antiviral.2015.10.009_b0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.antiviral.2015.06.014","article-title":"Chronic hepatitis B: a wave of new therapies on the horizon","author":"Block","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.10.009_b0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.gastro.2007.11.002","article-title":"T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes","volume":"1","author":"Bohne","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.10.009_b0030","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","article-title":"Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues","volume":"4","author":"Boni","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.10.009_b0035","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.virol.2012.04.007","article-title":"Optimization of immune responses induced by therapeutic vaccination with cross-reactive antigens in a humanized hepatitis B surface antigen transgenic mouse model","volume":"1","author":"Bourgine","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2015.10.009_b0040","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.tim.2015.01.013","article-title":"Towards an HIV-1 cure: measuring the latent reservoir","volume":"4","author":"Bruner","year":"2015","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0045","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1007\/s00535-013-0762-9","article-title":"B and T lymphocyte attenuator is highly expressed on intrahepatic T cells during chronic HBV infection and regulates their function","volume":"12","author":"Cai","year":"2013","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0050","doi-asserted-by":"crossref","DOI":"10.1007\/s10238-015-0373-2","article-title":"Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result","author":"Cai","year":"2015","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.antiviral.2015.10.009_b0055","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s10753-012-9525-7","article-title":"Intrahepatic expression of programmed death-1 and its ligands in patients with HBV-related acute-on-chronic liver failure","volume":"1","author":"Cao","year":"2013","journal-title":"Inflammation"},{"key":"10.1016\/j.antiviral.2015.10.009_b0060","doi-asserted-by":"crossref","first-page":"e14626","DOI":"10.1371\/journal.pone.0014626","article-title":"Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection","volume":"2","author":"Cavenaugh","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2015.10.009_b0065","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.antiviral.2015.07.006","article-title":"Treatment of chronic hepatitis B with pattern recognition receptor agonists: current status and potential for a cure","author":"Chang","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.10.009_b0070","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.antiviral.2012.10.001","article-title":"The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy","volume":"3","author":"Chang","year":"2012","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.10.009_b0075","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nm.3831","article-title":"Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection","volume":"4","author":"Chen","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2015.10.009_b0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","article-title":"Hepatitis B virus immunopathogenesis","author":"Chisari","year":"1995","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0085","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/jvh.12214","article-title":"2-amino-N-(2,6-dichloropyridin-3-yl)acetamide derivatives as a novel class of HBV capsid assembly inhibitor","volume":"12","author":"Cho","year":"2014","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2015.10.009_b0090","doi-asserted-by":"crossref","DOI":"10.1111\/liv.12845","article-title":"Clonal evolution of multidrug resistant hepatitis B virus during entecavir rescue therapy","author":"Chon","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2015.10.009_b0095","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1128\/JVI.02111-12","article-title":"A vesicular stomatitis virus-based therapeutic vaccine generates a functional CD8 T cell response to hepatitis B virus in transgenic mice","volume":"5","author":"Cobleigh","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0100","doi-asserted-by":"crossref","first-page":"641","DOI":"10.4049\/jimmunol.1202448","article-title":"The depletion of NK cells prevents T cell exhaustion to efficiently control disseminating virus infection","volume":"2","author":"Cook","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0105","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1586\/erv.10.162","article-title":"Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV safety and efficacy","volume":"4","author":"Cooper","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.antiviral.2015.10.009_b0110","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1086\/533467","article-title":"CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5years","volume":"8","author":"Cooper","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.10.009_b0115","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1128\/JVI.02384-08","article-title":"Treatment of chronic viral hepatitis in woodchucks by prolonged intrahepatic expression of interleukin-12","volume":"6","author":"Crettaz","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0120","doi-asserted-by":"crossref","first-page":"e1003798","DOI":"10.1371\/journal.ppat.1003798","article-title":"Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virus-specific CD8+ T cells and efficiently reduces chronic retroviral loads","volume":"12","author":"Dietze","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2015.10.009_b0125","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2015.03.015","article-title":"Targeting hepatitis B virus cccDNA by CRISPR\/Cas9 nuclease efficiently inhibits viral replication","author":"Dong","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.10.009_b0130","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1128\/AAC.00541-07","article-title":"A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion","volume":"12","author":"Dougherty","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.10.009_b0135","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.antiviral.2007.06.014","article-title":"The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging","volume":"2","author":"Feld","year":"2007","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.10.009_b0140","doi-asserted-by":"crossref","first-page":"7436","DOI":"10.1016\/j.vaccine.2010.08.091","article-title":"The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines","volume":"46","author":"Feng","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2015.10.009_b0145","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1053\/j.gastro.2012.08.041","article-title":"Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV","volume":"6","author":"Fisicaro","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.10.009_b0150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/hep.25954","article-title":"Identification of an intrahepatic transcriptional signature associated with self-limiting infection in the woodchuck model of hepatitis B","volume":"1","author":"Fletcher","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.10.009_b0155","doi-asserted-by":"crossref","first-page":"15001","DOI":"10.1073\/pnas.1312772110","article-title":"Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)","volume":"37","author":"Fuller","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2015.10.009_b0160","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection","volume":"2","author":"Gane","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0165","doi-asserted-by":"crossref","first-page":"e63818","DOI":"10.1371\/journal.pone.0063818","article-title":"A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection","volume":"5","author":"Gardiner","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2015.10.009_b0170","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jhep.2010.10.025","article-title":"Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines","volume":"1","author":"Gehring","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0175","first-page":"227","article-title":"Hepadnavirus-induced liver cancer in woodchucks","volume":"2","author":"Gerin","year":"1989","journal-title":"Cancer Detect. Prev."},{"key":"10.1016\/j.antiviral.2015.10.009_b0180","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2015.06.008","article-title":"Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities","author":"Gish","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.10.009_b0185","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2015.06.019","article-title":"Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent","author":"Gish","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.10.009_b0190","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.284.5415.825","article-title":"Viral clearance without destruction of infected cells during acute HBV infection","volume":"284","author":"Guidotti","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2015.10.009_b0195","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2015.08.005","article-title":"Metabolism and function of hepatitis B virus cccDNA: implications for the development of cccDNA-targeting antiviral therapeutics","author":"Guo","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.10.009_b0200","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ccr.2009.08.021","article-title":"A lymphotoxin-driven pathway to hepatocellular carcinoma","volume":"4","author":"Haybaeck","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.antiviral.2015.10.009_b0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/373123a0","article-title":"Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection","volume":"6510","author":"Ho","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.10.009_b0210","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/hep.25959","article-title":"Simultaneous knockdown of multiple ligands of innate receptor NKG2D prevents natural killer cell-mediated fulminant hepatitis in mice","volume":"1","author":"Huang","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.10.009_b0215","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"9454","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2015.10.009_b0220","doi-asserted-by":"crossref","first-page":"e28871","DOI":"10.1371\/journal.pone.0028871","article-title":"Restored circulating invariant NKT cells are associated with viral control in patients with chronic hepatitis B","volume":"12","author":"Jiang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2015.10.009_b0225","doi-asserted-by":"crossref","first-page":"e1004210","DOI":"10.1371\/journal.ppat.1004210","article-title":"Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver","volume":"6","author":"Jo","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2015.10.009_b0230","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jhep.2009.12.005","article-title":"T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B","volume":"3","author":"Ju","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0235","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1084\/jem.192.7.921","article-title":"Natural killer T cell activation inhibits hepatitis B virus replication in vivo","volume":"7","author":"Kakimi","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2015.10.009_b0240","doi-asserted-by":"crossref","DOI":"10.1111\/jgh.12993","article-title":"Outcome of adefovir add-on lamivudine rescue therapy of up to 5years in patients with lamivudine-resistant chronic hepatitis B","author":"Kim","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0245","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1038\/mtna.2013.43","article-title":"A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus","author":"Koh","year":"2013","journal-title":"Mol. Ther. Nucl. Acids"},{"key":"10.1016\/j.antiviral.2015.10.009_b0250","doi-asserted-by":"crossref","first-page":"9297","DOI":"10.1128\/JVI.00506-12","article-title":"DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model","volume":"17","author":"Kosinska","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0255","doi-asserted-by":"crossref","first-page":"e1003391","DOI":"10.1371\/journal.ppat.1003391","article-title":"Combination of DNA prime\u2013adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model","volume":"6","author":"Kosinska","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2015.10.009_b0260","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2013.04.047","article-title":"T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice","volume":"2","author":"Krebs","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.10.009_b0265","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1084\/jem.20131333","article-title":"Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction","volume":"10","author":"Kurktschiev","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2015.10.009_b0270","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.26339","article-title":"Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance","volume":"1","author":"Lan","year":"2013","journal-title":"Hepatology"},{"issue":"1508\u20131517","key":"10.1016\/j.antiviral.2015.10.009_b0275","first-page":"1511","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"7","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.10.009_b0280","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"26","author":"Lau","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.10.009_b0285","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2012.10.039","article-title":"Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice","volume":"2","author":"Li","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.10.009_b0290","doi-asserted-by":"crossref","first-page":"e86927","DOI":"10.1371\/journal.pone.0086927","article-title":"Decreased peripheral natural killer cells activity in the immune activated stage of chronic hepatitis B","volume":"2","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2015.10.009_b0295","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/liv.12589","article-title":"Telbivudine therapy may shape CD4(+) T-cell response to prevent liver fibrosis in patients with chronic hepatitis B","volume":"3","author":"Li","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2015.10.009_b0300","article-title":"Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial","author":"Lim","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2015.10.009_b0305","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1038\/mtna.2014.38","article-title":"The CRISPR\/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo","author":"Lin","year":"2014","journal-title":"Mol. Ther. Nucl. Acids"},{"key":"10.1016\/j.antiviral.2015.10.009_b0310","doi-asserted-by":"crossref","first-page":"e1003856","DOI":"10.1371\/journal.ppat.1003856","article-title":"Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection","volume":"1","author":"Liu","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2015.10.009_b0315","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jhep.2005.11.036","article-title":"Cellular and virological mechanisms of HBV drug resistance","volume":"2","author":"Locarnini","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0320","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1128\/JVI.01613-07","article-title":"Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model","volume":"5","author":"Lu","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0325","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"6176","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2015.10.009_b0330","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/cmi.2014.112","article-title":"Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses","volume":"3","author":"Ma","year":"2015","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0335","first-page":"57","article-title":"NK cells: a double-edged sword in chronic hepatitis B virus infection","author":"Maini","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0340","first-page":"2045","article-title":"Nivolumab in the treatment of malignant melanoma: review of the literature","author":"Mashima","year":"2015","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.antiviral.2015.10.009_b0345","doi-asserted-by":"crossref","first-page":"S441","DOI":"10.1016\/S0168-8278(11)61116-1","article-title":"1114 anti-viral efficacy and induction of an antibody response against surface antigen with the TLR7 agonist GS-9620 in the woodchuck model of chronic HBV infection","author":"Menne","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0350","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2014.12.026","article-title":"Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B","volume":"6","author":"Menne","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0355","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.virol.2007.11.032","article-title":"Antiviral therapy with entecavir combined with post-exposure \u201cprime-boost\u201d vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection","volume":"2","author":"Miller","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2015.10.009_b0360","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.4049\/jimmunol.152.10.4976","article-title":"MHC class I and non-MHC-linked capacity for generating an anti-viral CTL response determines susceptibility to CTL exhaustion and establishment of virus persistence in mice","volume":"10","author":"Moskophidis","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0365","doi-asserted-by":"crossref","first-page":"e47648","DOI":"10.1371\/journal.pone.0047648","article-title":"Upregulation of the Tim-3\/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection","volume":"10","author":"Nebbia","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2015.10.009_b0370","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1128\/AAC.01003-13","article-title":"Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro","volume":"11","author":"Noordeen","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.10.009_b0375","doi-asserted-by":"crossref","first-page":"10464","DOI":"10.1128\/JVI.05039-11","article-title":"Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope","volume":"20","author":"Oh","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0380","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/hep.25667","article-title":"Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B","volume":"2","author":"Otano","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.10.009_b0385","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"12","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2015.10.009_b0390","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1074-7613(00)80628-7","article-title":"Comparison of activation versus induction of unresponsiveness of virus-specific CD4+ and CD8+ T cells upon acute versus persistent viral infection","volume":"4","author":"Oxenius","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.antiviral.2015.10.009_b0395","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.4049\/jimmunol.1201613","article-title":"TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity","volume":"9","author":"Pasetto","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0400","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1172\/JCI118902","article-title":"Long-lasting memory T cell responses following self-limited acute hepatitis B","volume":"5","author":"Penna","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2015.10.009_b0405","doi-asserted-by":"crossref","first-page":"e1001227","DOI":"10.1371\/journal.ppat.1001227","article-title":"Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection","volume":"12","author":"Peppa","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2015.10.009_b0410","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1084\/jem.20121172","article-title":"Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion","volume":"1","author":"Peppa","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2015.10.009_b0415","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(76)90598-5","article-title":"Modification of chronic hepatitis-B virus infection in chimpanzees by administration of an interferon inducer","volume":"7989","author":"Purcell","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2015.10.009_b0420","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2014.10.001","article-title":"Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient","volume":"2","author":"Qasim","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0425","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/hep.23936","article-title":"The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function","volume":"6","author":"Raziorrouh","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.10.009_b0430","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nm.3251","article-title":"Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells","volume":"7","author":"Rehermann","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2015.10.009_b0435","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/nm1096-1104","article-title":"The hepatitis B virus persists for decades after patients\u2019 recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response","volume":"10","author":"Rehermann","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2015.10.009_b0440","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1172\/JCI118592","article-title":"Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection","volume":"7","author":"Rehermann","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2015.10.009_b0445","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01184-15","article-title":"Virus-Like vesicle-based therapeutic vaccine vectors for chronic hepatitis B virus infection","author":"Reynolds","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0450","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/hep.20888","article-title":"Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity","volume":"5","author":"Rigopoulou","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.10.009_b0455","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1128\/JVI.13.6.1231-1236.1974","article-title":"DNA polymerase in the core of the human hepatitis B virus candidate","volume":"6","author":"Robinson","year":"1974","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0460","doi-asserted-by":"crossref","first-page":"12266","DOI":"10.1128\/JVI.01597-09","article-title":"Semliki forest virus expressing interleukin-12 induces antiviral and antitumoral responses in woodchucks with chronic viral hepatitis and hepatocellular carcinoma","volume":"23","author":"Rodriguez-Madoz","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0465","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.patbio.2010.04.005","article-title":"The woodchuck: a model for therapeutic vaccination against hepadnaviral infection","volume":"4","author":"Roggendorf","year":"2010","journal-title":"Pathol. Biol. (Paris)"},{"key":"10.1016\/j.antiviral.2015.10.009_b0470","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1172\/JCI119498","article-title":"Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B","volume":"12","author":"Rossol","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2015.10.009_b0475","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/hep.24249","article-title":"Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection","volume":"5","author":"Schurich","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.10.009_b0480","doi-asserted-by":"crossref","first-page":"e1003208","DOI":"10.1371\/journal.ppat.1003208","article-title":"The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells","volume":"3","author":"Schurich","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2015.10.009_b0485","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0042-6822(90)90297-5","article-title":"Expression pattern of the hepatitis B virus genome in transfected mouse fibroblasts","volume":"1","author":"Seifer","year":"1990","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2015.10.009_b0490","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hep.22609","article-title":"Llama-derived single-domain intrabodies inhibit secretion of hepatitis B virions in mice","volume":"1","author":"Serruys","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.10.009_b0495","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3892\/mmr.2014.2826","article-title":"Lymphotoxin beta receptor activation promotes bladder cancer in a nuclear factor-kappaB-dependent manner","volume":"2","author":"Shen","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.antiviral.2015.10.009_b0500","first-page":"e117741","article-title":"Effects of entecavir on hepatitis B virus covalently closed circular DNA in hepatitis B e antigen-positive patients with hepatitis B","volume":"2","author":"Shi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2015.10.009_b0505","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nm.3550","article-title":"Opening fronts in HIV vaccine development: targeting reservoirs to clear and cure","volume":"5","author":"Siliciano","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2015.10.009_b0510","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jaci.2014.05.026","article-title":"Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1","volume":"1","author":"Siliciano","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0515","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiv180","article-title":"Natural killer cell characteristics in patients with chronic hepatitis B virus (HBV) infection are associated with HBV surface antigen clearance after combination treatment with pegylated interferon alfa-2a and adefovir","author":"Stelma","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.10.009_b0520","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1128\/JVI.46.2.626-628.1983","article-title":"Structural relationships between minor and major proteins of hepatitis B surface antigen","volume":"2","author":"Stibbe","year":"1983","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0525","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/jmr.801","article-title":"BAY 41-4109 has multiple effects on hepatitis B virus capsid assembly","volume":"6","author":"Stray","year":"2006","journal-title":"J. Mol. Recognit."},{"key":"10.1016\/j.antiviral.2015.10.009_b0530","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/jmv.24006","article-title":"Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B","volume":"9","author":"Su","year":"2015","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0535","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0092-8674(82)90157-X","article-title":"Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate","volume":"2","author":"Summers","year":"1982","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2015.10.009_b0540","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/cmi.2014.91","article-title":"NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma","volume":"3","author":"Sun","year":"2015","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0545","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/ki.2009.454","article-title":"Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine","volume":"3","author":"Surquin","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.antiviral.2015.10.009_b0550","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.antiviral.2004.12.005","article-title":"Effects of IL-12 and IL-18 on HBcAg-specific cytokine production by CD4 T lymphocytes of children with chronic hepatitis B infection","volume":"1","author":"Szkaradkiewicz","year":"2005","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.10.009_b0555","doi-asserted-by":"crossref","first-page":"946","DOI":"10.4161\/mabs.26390","article-title":"A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity","volume":"6","author":"Tan","year":"2013","journal-title":"mAbs-Austin"},{"key":"10.1016\/j.antiviral.2015.10.009_b0560","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2015.04.002","article-title":"The hepatitis B virus ribonuclease H as a drug target","author":"Tavis","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.10.009_b0565","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/liv.12272","article-title":"Intrahepatic natural killer cell activation, but not function, is associated with HBsAg levels in patients with HBeAg-negative chronic hepatitis B","volume":"3","author":"Tjwa","year":"2014","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2015.10.009_b0570","doi-asserted-by":"crossref","first-page":"e39179","DOI":"10.1371\/journal.pone.0039179","article-title":"PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model","volume":"6","author":"Tzeng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2015.10.009_b0575","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3851\/IMP2152","article-title":"In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations","volume":"5","author":"Wang","year":"2012","journal-title":"Antiviral Ther."},{"key":"10.1016\/j.antiviral.2015.10.009_b0580","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7150\/ijms.11687","article-title":"Delayed reduction of hepatitis B viral load and dynamics of adefovir-resistant variants during adefovir plus entecavir combination rescue therapy","volume":"5","author":"Wang","year":"2015","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.antiviral.2015.10.009_b0585","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/299740a0","article-title":"Cloned HBV DNA causes hepatitis in chimpanzees","volume":"5885","author":"Will","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.10.009_b0590","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cgh.2013.01.026","article-title":"Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency","volume":"8","author":"Wong","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0595","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/j.gastro.2009.09.018","article-title":"Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis B virus e antigen seroconversion","volume":"1","author":"Wu","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.10.009_b0600","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/eji.201141852","article-title":"Blockade of Tim-3 signaling restores the virus-specific CD8(+) T-cell response in patients with chronic hepatitis B","volume":"5","author":"Wu","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0605","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1128\/AAC.01091-13","article-title":"Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly","volume":"11","author":"Wu","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.10.009_b0610","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00996-14","article-title":"Polyinosinic\u2013polycytidylic acid treatment leads to the interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model","author":"Wu","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0615","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.bjid.2015.05.006","article-title":"Natural killer cells in hepatitis B virus infection","volume":"4","author":"Wu","year":"2015","journal-title":"Braz. J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.10.009_b0620","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.intimp.2006.12.007","article-title":"IL-12 promotes HBV-specific central memory CD8+ T cell responses by PBMCs from chronic hepatitis B virus carriers","volume":"5","author":"Xiong","year":"2007","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0625","doi-asserted-by":"crossref","first-page":"e2565","DOI":"10.1371\/journal.pone.0002565","article-title":"A randomized controlled phase IIb trial of antigen\u2013antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients","volume":"7","author":"Xu","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2015.10.009_b0630","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jhep.2013.05.003","article-title":"Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings","volume":"3","author":"Xu","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0635","doi-asserted-by":"crossref","first-page":"186","DOI":"10.5009\/gnl.2014.8.2.186","article-title":"The expression of programmed death-1 in circulating CD4+ and CD8+ T cells during hepatitis B virus infection progression and its correlation with clinical baseline characteristics","volume":"2","author":"Xu","year":"2014","journal-title":"Gut Liver"},{"key":"10.1016\/j.antiviral.2015.10.009_b0640","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.antiviral.2014.04.002","article-title":"Benzimidazole derivative, BM601, a novel inhibitor of hepatitis B virus and HBsAg secretion","author":"Xu","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.10.009_b0645","doi-asserted-by":"crossref","first-page":"9200","DOI":"10.1128\/JVI.00933-15","article-title":"The Interferon-inducible protein tetherin inhibits hepatitis B virus virion secretion","volume":"18","author":"Yan","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0650","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.vaccine.2006.11.019","article-title":"Therapeutic effect of hepatitis B surface antigen\u2013antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients","volume":"10","author":"Yao","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2015.10.009_b0655","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1021\/jm200696v","article-title":"Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion","volume":"16","author":"Yu","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2015.10.009_b0660","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.4049\/jimmunol.1203449","article-title":"IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier","volume":"8","author":"Zeng","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0665","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00430-014-0370-1","article-title":"Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection","volume":"1","author":"Zhang","year":"2015","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0670","doi-asserted-by":"crossref","first-page":"e26196","DOI":"10.1371\/journal.pone.0026196","article-title":"The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection","volume":"10","author":"Zhang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2015.10.009_b0675","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1499-3872(13)60061-2","article-title":"Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B","volume":"4","author":"Zhang","year":"2013","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"10.1016\/j.antiviral.2015.10.009_b0680","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/jvh.12261","article-title":"Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12weeks of antiviral treatment were associated with HBeAg loss","volume":"12","author":"Zheng","year":"2014","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2015.10.009_b0685","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/cei.12597","article-title":"Activated natural killer cells accelerate liver damage in patients with chronic hepatitis B virus infection","volume":"3","author":"Zheng","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.antiviral.2015.10.009_b0690","first-page":"4","article-title":"Antiviral therapies and prospects for a cure of chronic hepatitis B","author":"Zoulim","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.antiviral.2015.10.009_b0695","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"5","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215300103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215300103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T16:19:23Z","timestamp":1692116363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215300103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":139,"alternative-id":["S0166354215300103"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.10.009","relation":{},"ISSN":["0166-3542"],"issn-type":[{"type":"print","value":"0166-3542"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the \u201cmagic bullet\u201d to kill cccDNA","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}